ITGA2 Mediates the Resistance of Hepatocellular Carcinoma to Lenvatinib by Activating the AKT/FOXO3A Signaling Pathway
- Cancers (Basel). 2025 Aug 29;17(17):2846. doi: 10.3390/cancers17172846.
Affiliations
- 1. Engineering Research Center for New Materials and Precision Treatment Technology of Malignant Tumors Therapy, The Second Affiliated Hospital, Dalian Medical University, Dalian 116023, China.
- 2. Engineering Technology Research Center for Translational Medicine, The Second Affiliated Hospital, Dalian Medical University, Dalian 116023, China.
- 3. Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, 467 Zhongshan Road, Dalian 116023, China.
- 4. Department of Radiotherapy, The Seventh Afffliated Hospital of Sun Yat-Sen University, Shenzhen 518107, China.
- 5. Department of General Surgery, The Seventh Afffliated Hospital of Sun Yat-Sen University, Shenzhen 518107, China.
PMID: 40940943
DOI: 10.3390/cancers17172846
Abstract
The global incidence of primary liver Cancer ranks sixth among malignant tumors, while its mortality rate ranks third and is the second leading cause of cancer-related deaths in China [...].
Keywords
E7820; drug resistance; hepatocellular carcinoma; integrin; lenvatinib.
Products
Inhibitors & Agonists
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-
Other Products
-
Cat. No.Product NameCategory/Application